- US12617854utility2026Humanized or Chimeric CD3 Antibodies0 cites
- US12595316utility2026Bispecific and Multispecific Antibodies and Method for Isolation of Such0 cites
- US12589150utility2026Antibodies Binding AXL0 cites
- US12435154utility2025Bispecific Antibodies Against CD3 and CD200 cites
- US12421319utility2025Binding Agents That Bind OX40 (CD134) and Method of Use Thereof to Treat Disease0 cites
- US12415859utility2025Methods of Producing Heterodimeric Antibodies0 cites
- US12351650utility2025Antibodies Binding to Fibroblast Activation Protein Alpha and Death Receptor 40 cites
- US12247065utility2025Method for Producing a Controlled Mixture of Two or More Different Antibodies0 cites
- US12115227utility2024Formulation for Antibody and Drug Conjugate Thereof0 cites
- US11970544utility2024Antibodies0 cites
- US11932693utility2024Monoclonal Antibodies Directed Against Programmed Death-1 Protein and Their Use in Medicine0 cites
- US11866514utility2024Heterodimeric Antibody Fc-containing Proteins and Methods for Production Thereof0 cites
- US11858995utility2024Bispecific Antibodies Against CD3 and CD20 for Treating Chronic Lymphocytic Leukemia0 cites
- US11845805utility2023Bispecific Antibody Against CD3 and CD20 in Combination Therapy for Treating Diffuse Large B-cell Lymphoma0 cites
- US11814437utility2023Antibodies Binding to CD30 and CD30 cites
- US11814411utility2023Nucleic Acid Molecules Encoding Binding Agents to CD40 and 4-1BB (CD137)0 cites
- US11795214utility2023Modulation of Complement-dependent Cytotoxicity Through Modifications of the C-terminus of Antibody Heavy Chains0 cites
- US11613575utility2023Humanized or Chimeric CD3 Antibodies0 cites
Page 1 of 2Next →